[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354104-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354104-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pancancer-fine-mapping-of-mutational-intolerance-identifies-chek1-as-an-immunosuppressive-driver-in-lung-adenocarcinoma","Pancancer Fine-Mapping of Mutational Intolerance Identifies CHEK1 as an Immunosuppressive Driver in Lung Adenocarcinoma","","Mutation-intolerant genes (MIGs) are constrained in tumors yet variable in normal tissues, making them critical for cancer survival. This study introduces miDriver, a computational framework using pancancer-normal mutation contrasts to identify 1,020 MIGs across 8,096 tumors from 13 cancer types. CRISPR screening highlights MIG vulnerabilities, especially CHEK1, whose suppression reduces tumor proliferation and migration. Single-cell and spatial analyses link CHEK1-high states to immune-suppressed, M2-like macrophage proximity. Mechanistically, CHEK1 drives p53 phosphorylation to upregulate MIF, activating MIF–CD74 signaling and reversing immunosuppression in vivo; higher CHEK1 correlates with weaker anti-PD-1 response.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pancancer-fine-mapping-of-mutational-intolerance-identifies-chek1-as-an-immunosuppressive-driver-in-lung-adenocarcinoma/354104/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pancancer-fine-mapping-of-mutational-intolerance-identifies-chek1-as-an-immunosuppressive-driver-in-lung-adenocarcinoma/354104.png","ImageObject",300,407,{"name":42,"@type":43},"Bintang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What computational method is developed to identify mutation-intolerant genes (MIGs)?","Question",{"text":63,"@type":64},"The study develops miDriver, a framework that uses pancancer-normal mutation contrasts to identify MIGs across tumors and cancer types.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does CHEK1 suppression affect lung adenocarcinoma cells?",{"text":68,"@type":64},"CRISPR screening indicates that targeting CHEK1 impairs tumor proliferation and migration.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism links CHEK1 to immune suppression and M2-like macrophage polarization?",{"text":72,"@type":64},"CHEK1 promotes p53 phosphorylation to increase MIF expression and secretion, which activates the MIF–CD74 axis to drive M2-like macrophage polarization.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354104,1790878366,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":98,"preview_page_count":33,"preview_urls":145},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Advanced Science    \n[www.advancedscience.com](www.advancedscience.com)  \n RESEARCH ARTICLE   \nPancancer Fine-Mapping of Mutational Intolerance Identifies CHEK1 as an Immunosuppressive Driver in Lung Adenocarcinoma  \nTao Wang1, 2, 3  Hongyu Zhao4, 5, 6, 7  Xiaojie Sun8  Yuqi Ding9  Zhipeng Zhu1, 2, 3  Xiaotong Yu1, 2, 3  Rongyi Zhu10 Dan Wang8  Kailong Li10  Yang Liu11  Li-Bin Wang12  Xiaolu Zhao4, 5, 6, 7  Baojun Suo13  Hongsen Bi14  Peipei Zhang9, 15  Tong Liu1, 2, 3  Fengbiao Mao1, 2, 3   \n1 Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China  2 Cancer Center, Peking University Third Hospital, Beijing, China  3 Beijing Key Laboratory for Interdisciplinary Research in Gastrointestinal Oncology (BLGO), Beijing, China  4 State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China  5National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital), Beijing, China  6 Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education, Beijing, China  7 Beijing Key Laboratory of Collaborative Innovation in Frontier Technologies for Population Quality, Beijing, China  8 Department of Pathology, Zibo Central hospital, Zibo, Shandong, China  9 Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China  10 Department of Biochemistry and Molecular Biology, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China  11 Department of Medical Genetics, Center for Medical Genetics, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing, China  12 Department of Cell Biology, School of Basic Medical Sciences, Peking University Stem Cell Research Center, Peking University Health Science Center, Peking University, Beijing, China  13 Department of Gastroenterology, Peking University Third Hospital, Beijing, China  14 Department of Plastic Surgery, Peking University Third Hospital, Beijing, China  15Key Laboratory for Neuroscience, Ministry of Education/National Health and Family Planning Commission, Peking University, Beijing, China  \nCorrespondence: Baojun Suo ([suobaojun2013@126.com](suobaojun2013@126.com))  Hongsen Bi (bihongsen@bjmu.edu.cn)  Peipei Zhang (peipei.zhang@pku.edu.cn)  Tong Liu ([tongtongliu@bjmu.edu.cn](tongtongliu@bjmu.edu.cn))  Fengbiao Mao (fengbiaomao@bjmu.edu.cn)  \nReceived: 25 October 2025  Revised: 15 February 2026  Accepted: 15 February 2026  \nKeywords: CHEK1 | CRISPR base-editing screens | immunosuppression | lung adenocarcinoma | M2-like macrophage | multi-omics profiling | mutational intolerance  \nABSTRACT  \nMutation-intolerant genes (MIGs), which are constrained in tumors yet variable in normal tissues, are critical for cancer survival. Herein, we developed miDriver, a computational framework using pancancer-normal mutation contrasts to identify 1,020 MIGs across 8,096 tumors of 13 cancer types. Strikingly, MIGs are highly associated with synthetic lethality, cell-cycle progression, and clinical outcome. CRISPR screening reveals MIGs, especially CHEK1, as cancer-specific vulnerabilities, whose suppression impairs tumor proliferation and migration. Single-cell transcriptomics reveals a CHEK1-high subpopulation exhibiting stem-like and immune-suppressed features, linking tumor-intrinsic fitness to microenvironment remodeling. Multiplexed immunofluorescence revealed that CHEK1 and MIF are co-expressed in tumor cells, and CHEK1-high tumor cells exhibit closer spatial proximity to M2-like macrophages. Mechanistically, CHEK1 promotes p53 phosphorylation to upregulate MIF expression and secretion, thereby driving M2-like macrophage polarization via the MIF–CD74 axis. In vivo, tar","cbCaiaFomeWsLPAh","https://ap.wps.com/l/cbCaiaFomeWsLPAh","pdf",5802594,24,"English","# Abstract\n# Introduction","[{\"question\":\"What computational method is developed to identify mutation-intolerant genes (MIGs)?\",\"answer\":\"The study develops miDriver, a framework that uses pancancer-normal mutation contrasts to identify MIGs across tumors and cancer types.\"},{\"question\":\"How does CHEK1 suppression affect lung adenocarcinoma cells?\",\"answer\":\"CRISPR screening indicates that targeting CHEK1 impairs tumor proliferation and migration.\"},{\"question\":\"What mechanism links CHEK1 to immune suppression and M2-like macrophage polarization?\",\"answer\":\"CHEK1 promotes p53 phosphorylation to increase MIF expression and secretion, which activates the MIF–CD74 axis to drive M2-like macrophage polarization.\"}]","Pancancer Fine-Mapping of Mutational Intolerance Identifies CHEK1 as an Immunosuppressive Driver in Lung Adenocarcinoma | PDF",1790108981,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63a8a1d10dae33011fb15dea8b1d477b.webp",983,1283,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff8335b3480b175d961f67508429688e.webp",982,1281,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f545b74ebf5f13695c412422447b283.webp",981,1280,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3319a928192c6c9244bbc0e3cabf97e4.webp",980,1279]